In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adamis Pharmaceuticals Corporation

http://www.adamispharmaceuticals.com/

Latest From Adamis Pharmaceuticals Corporation

Cage Fighting: Novel Drugs From MNCs, Chinese Rivals Compete In China Reimbursement Sector

After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.

China Reimbursement

Finance Watch: VC Mega-Rounds Surge Again, Led By Acelyrin’s $300m Series C

Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals. 

Financing Innovation

Five Potential Blockbuster Oncology Approvals To Look Out For In 2023

With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.

Cancer Approvals

Chinese Firms' Delisting Uncertainty Lifted For Now But Clock Ticking

A new bilateral agreement between securities regulatory authorities in the US and China is being seen as a welcome first step in addressing issues around US inspections of auditors of US-listed Chinese firms, but implementation will be key. 

Financing Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Biosyn Inc.
    • Cellegy Holdings Inc
    • US Compounding, Inc.
UsernamePublicRestriction

Register